Subscribe to RSS
DOI: 10.1055/a-2771-7417
Local Excision in the Era of Total Neoadjuvant Therapy
Authors
Funding Information The authors have no financial disclosures to report.
Abstract
Total neoadjuvant therapy (TNT) for rectal cancer has allowed for organ preservation in cases of complete response. At first, organ preservation was accomplished by a nonoperative approach that avoided proctectomy altogether. However, nonoperative management is not appropriate in cases where the patient does not have a complete response, in the setting of local recurrence, or in early-stage rectal cancer where TNT was not previously indicated. Local excision of rectal tumors paired with TNT expands organ preservation strategies, allowing for resection to address the primary tumor without the risks and negative functional effects associated with proctectomy. In this brief review, we discuss the role of local excision in concert with total neoadjuvant treatment for early-stage tumors, in an organ-preserving strategy for residual disease after total neoadjuvant treatment, and for local regrowth after total neoadjuvant treatment.
Publication History
Article published online:
09 January 2026
© 2026. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Heald RJ, Ryall RD. Recurrence and survival after total mesorectal excision for rectal cancer. Lancet 1986; 1 (8496) 1479-1482
- 2 Chau I, Allen M, Cunningham D. et al. Neoadjuvant systemic fluorouracil and mitomycin C prior to synchronous chemoradiation is an effective strategy in locally advanced rectal cancer. Br J Cancer 2003; 88 (07) 1017-1024
- 3 Cedermark B, Dahlberg M, Glimelius B, Påhlman L, Rutqvist LE, Wilking N. Swedish Rectal Cancer Trial. Improved survival with preoperative radiotherapy in resectable rectal cancer. N Engl J Med 1997; 336 (14) 980-987
- 4 Sauer R, Becker H, Hohenberger W. et al; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351 (17) 1731-1740
- 5 Rastogi P, Anderson SJ, Bear HD. et al. Preoperative chemotherapy: updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27. J Clin Oncol 2008; 26 (05) 778-785
- 6 van der Valk MJM, Marijnen CAM, van Etten B. et al; Collaborative investigators. Compliance and tolerability of short-course radiotherapy followed by preoperative chemotherapy and surgery for high-risk rectal cancer - Results of the international randomized RAPIDO-trial. Radiother Oncol 2020; 147: 75-83
- 7 Conroy T, Castan F, Etienne PL. et al. Total neoadjuvant therapy with mFOLFIRINOX versus preoperative chemoradiotherapy in patients with locally advanced rectal cancer: long-term results of the UNICANCER-PRODIGE 23 trial. Ann Oncol 2024; 35 (10) 873-881
- 8 Buess G, Kipfmüller K, Hack D, Grüssner R, Heintz A, Junginger T. Technique of transanal endoscopic microsurgery. Surg Endosc 1988; 2 (02) 71-75
- 9 Danish Colorectal Cancer Group. . Treatment of early rectal cancer. Published 2018. Accessed January 2, 2026 at: https://dccg.dk/wp-content/uploads/2018/10/2018_Behandling-af-tidlig-kolorektal-cancer-i-rectum-vers-1_2.pdf
- 10 Buess G, Kipfmüller K, Ibald R. et al. Clinical results of transanal endoscopic microsurgery. Surg Endosc 1988; 2 (04) 245-250
- 11 Lee L, Edwards K, Hunter IA. et al. Quality of local excision for rectal neoplasms using transanal endoscopic microsurgery versus transanal minimally invasive surgery: a multi-institutional matched analysis. Dis Colon Rectum 2017; 60 (09) 928-935
- 12 Benson III AB, Venook AP, Adam M. et al. Rectal Cancer, Version 4.2025, NCCN Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. Published 2025. Accessed November 17, 2025 at: https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1461#:~:text=Guidelines-,NCCN%20Guidelines,-Version%204.2025
- 13 van Oostendorp SE, Smits LJH, Vroom Y. et al. Local recurrence after local excision of early rectal cancer: a meta-analysis of completion TME, adjuvant (chemo)radiation, or no additional treatment. Br J Surg 2020; 107 (13) 1719-1730
- 14 Hoedema R. Rectal Cancer: Local Excision. In: ASCRS Textbook of Colon and Rectal Surgery. 4th ed. Springer Nature Switzerland AG; 2025
- 15 Paty PB, Nash GM, Baron P. et al. Long-term results of local excision for rectal cancer. Ann Surg 2002; 236 (04) 522-529 , discussion 529–530
- 16 Garcia-Aguilar J, Mellgren A, Sirivongs P, Buie D, Madoff RD, Rothenberger DA. Local excision of rectal cancer without adjuvant therapy: a word of caution. Ann Surg 2000; 231 (03) 345-351
- 17 Sun G, Tang Y, Li X, Meng J, Liang G. Analysis of 116 cases of rectal cancer treated by transanal local excision. World J Surg Oncol 2014; 12: 202
- 18 Nascimbeni R, Burgart LJ, Nivatvongs S, Larson DR. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002; 45 (02) 200-206
- 19 Ricciardi R, Madoff RD, Rothenberger DA, Baxter NN. Population-based analyses of lymph node metastases in colorectal cancer. Clin Gastroenterol Hepatol 2006; 4 (12) 1522-1527
- 20 Hallam S, Messenger DE, Thomas MG. A systematic review of local excision after neoadjuvant therapy for rectal cancer: are ypT0 tumors the limit?. Dis Colon Rectum 2016; 59 (10) 984-997
- 21 Nair RM, Siegel EM, Chen DT. et al. Long-term results of transanal excision after neoadjuvant chemoradiation for T2 and T3 adenocarcinomas of the rectum. J Gastrointest Surg 2008; 12 (10) 1797-1805 , discussion 1805–1806
- 22 Kim CJ, Yeatman TJ, Coppola D. et al. Local excision of T2 and T3 rectal cancers after downstaging chemoradiation. Ann Surg 2001; 234 (03) 352-358 , discussion 358–359
- 23 Borschitz T, Wachtlin D, Möhler M, Schmidberger H, Junginger T. Neoadjuvant chemoradiation and local excision for T2-3 rectal cancer. Ann Surg Oncol 2008; 15 (03) 712-720
- 24 Lezoche E, Baldarelli M, Lezoche G, Paganini AM, Gesuita R, Guerrieri M. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012; 99 (09) 1211-1218
- 25 Garcia-Aguilar J, Renfro LA, Chow OS. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015; 16 (15) 1537-1546
- 26 Stijns RCH, de Graaf EJR, Punt CJA. et al; CARTS Study Group. Long-term oncological and functional outcomes of chemoradiotherapy followed by organ-sparing transanal endoscopic microsurgery for distal rectal cancer: the CARTS study. JAMA Surg 2019; 154 (01) 47-54
- 27 Bach SP, Gilbert A, Brock K. et al; TREC collaborators. Radical surgery versus organ preservation via short-course radiotherapy followed by transanal endoscopic microsurgery for early-stage rectal cancer (TREC): a randomised, open-label feasibility study. Lancet Gastroenterol Hepatol 2021; 6 (02) 92-105
- 28 Rullier E, Vendrely V, Asselineau J. et al. Organ preservation with chemoradiotherapy plus local excision for rectal cancer: 5-year results of the GRECCAR 2 randomised trial. Lancet Gastroenterol Hepatol 2020; 5 (05) 465-474
- 29 Serra-Aracil X, Pericay C, Cidoncha A. et al; TAUTEM Collaborative Group. Chemoradiotherapy and local excision vs total mesorectal excision in T2-T3ab, N0, M0 rectal cancer: the TAUTEM randomized clinical trial. JAMA Surg 2025; 160 (07) 783-793
- 30 Mohiuddin M, Marks G, Bannon J. High-dose preoperative radiation and full thickness local excision: a new option for selected T3 distal rectal cancers. Int J Radiat Oncol Biol Phys 1994; 30 (04) 845-849
- 31 Hupkens BJP, Maas M, Martens MH. et al. Organ preservation in rectal cancer after chemoradiation: should we extend the observation period in patients with a clinical near-complete response?. Ann Surg Oncol 2018; 25 (01) 197-203
- 32 Martens MH, Maas M, Heijnen LA. et al. Long-term Outcome of an organ preservation program after neoadjuvant treatment for rectal cancer. J Natl Cancer Inst 2016; 108 (12) djw171
- 33 Denost Q, Rullier E, Rouanet P. et al. Total neoadjuvant treatment with mFolfirinox and chemoradiotherapy versus chemoradiotherapy for rectal preservation: the randomized GRECCAR12 trial. American Society of Colon and Rectal Surgeons Annual Scientific Meeting; 5/12/ 2025 , 2025; San Diego, CA.
- 34 Fernandez LM, Figueiredo NL, Habr-Gama A. et al. Salvage surgery with organ preservation for patients with local regrowth after watch and wait: is it still possible?. Dis Colon Rectum 2020; 63 (08) 1053-1062
- 35 Geubels BM, Meyer VM, van Westreenen HL, Beets GL, Grotenhuis BA. On Behalf Of The Dutch Watch And Wait Consortium. Role of local excision for suspected regrowth in a watch and wait strategy for rectal cancer. Cancers (Basel) 2022; 14 (13) 3071
- 36 Wang L, Zhang XY, Zhao YM. et al; Rectal Cancer Cooperative Group of Peking University Cancer Hospital. Intentional watch and wait or organ preservation surgery following neoadjuvant chemoradiotherapy plus consolidation CAPEOX for MRI-defined Low-risk rectal cancer: findings from a prospective phase 2 trial (PKUCH-R01 trial, NCT02860234). Ann Surg 2023; 277 (04) 647-654
- 37 São Julião GP, Karagkounis G, Fernandez LM. et al. Conditional survival in patients with rectal cancer and complete clinical response managed by watch and wait after chemoradiation: recurrence risk over time. Ann Surg 2020; 272 (01) 138-144
- 38 Verheij FS, Omer DM, Williams H. et al. Long-term results of organ preservation in patients with rectal adenocarcinoma treated with total neoadjuvant therapy: the randomized phase II OPRA trial. J Clin Oncol 2024; 42 (05) 500-506
- 39 Gani C, Fokas E, Polat B. et al. Organ preservation after total neoadjuvant therapy for locally advanced rectal cancer (CAO/ARO/AIO-16): an open-label, multicentre, single-arm, phase 2 trial. Lancet Gastroenterol Hepatol 2025; 10 (06) 562-572
- 40 Picotto S, Rega D, La Terra A, Muratore A, Delrio P. Local excision after regrowth in rectal sparing: a review on iterative rectal preservation after neoadjuvant treatment. Tech Coloproctol 2025; 29 (01) 177
- 41 van der Sande ME, Figueiredo N, Beets GL. Management and outcome of local regrowths in a watch-and-wait prospective cohort for complete responses in rectal cancer. Ann Surg 2021; 274 (06) e1056-e1062
- 42 Lai SH, Widmar M, Monson JRT, Fleming FJ, Morris AM, Vogel JD. US Rectal Cancer Research Group. Rectal cancer watch-and-wait management: experience of 545 patients from the US Rectal Cancer Research Group. Dis Colon Rectum 2025; 68 (02) 180-189
- 43 Boubaddi M, Pluchon A, Marichez A. et al. Local regrowth after a watch-and-wait strategy for middle and low rectal cancer: is organ preservation still feasible?. Ann Surg Oncol 2025; 32 (13) 9502-9509
- 44 Fernandez LM, São Julião GP, Renehan AG. et al; International Watch & Wait Database (IWWD) Consortium. The risk of distant metastases in patients with clinical complete response managed by watch and wait after neoadjuvant therapy for rectal cancer: the influence of local regrowth in the International Watch and Wait Database. Dis Colon Rectum 2023; 66 (01) 41-49
- 45 van der Valk MJM, Hilling DE, Bastiaannet E. et al; IWWD Consortium. Long-term outcomes of clinical complete responders after neoadjuvant treatment for rectal cancer in the International Watch & Wait Database (IWWD): an international multicentre registry study. Lancet 2018; 391 (10139): 2537-2545
- 46 Dulskas A, Petrauskas V, Kavaliauskas P, Sapoka V, Samalavicius NE. Short-term clinical and functional results of rectal wall suture defect after transanal endoscopic microsurgery-a prospective cohort study. Langenbecks Arch Surg 2022; 407 (05) 2035-2040
- 47 Lu YH, Lu JY, Qiu XY. et al. [Prognostic analysis of local excision following neoadjuvant therapy for rectal cancer: a single-center study]. Zhonghua Wei Chang Wai Ke Za Zhi 2025; 28 (11) 1260-1266
- 48 Marks JH, Valsdottir EB, DeNittis A. et al. Transanal endoscopic microsurgery for the treatment of rectal cancer: comparison of wound complication rates with and without neoadjuvant radiation therapy. Surg Endosc 2009; 23 (05) 1081-1087
- 49 Perez RO, Habr-Gama A, São Julião GP, Proscurshim I, Scanavini Neto A, Gama-Rodrigues J. Transanal endoscopic microsurgery for residual rectal cancer after neoadjuvant chemoradiation therapy is associated with significant immediate pain and hospital readmission rates. Dis Colon Rectum 2011; 54 (05) 545-551
- 50 Verseveld M, de Graaf EJ, Verhoef C. et al; CARTS Study Group. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015; 102 (07) 853-860
- 51 Issa N, Murninkas A, Schmilovitz-Weiss H, Agbarya A, Powsner E. Transanal endoscopic microsurgery after neoadjuvant chemoradiotherapy for rectal cancer. J Laparoendosc Adv Surg Tech A 2015; 25 (08) 617-624
- 52 Lee BC, Oh S, Lim SB, Yu CS, Kim JC. Transanal minimally-invasive surgery for treating patients with regressed rectal cancer after preoperative chemoradiotherapy. Ann Coloproctol 2017; 33 (02) 52-56
- 53 Serra-Aracil X, Pericay C, Badia-Closa J. et al. Short-term outcomes of chemoradiotherapy and local excision versus total mesorectal excision in T2-T3ab,N0,M0 rectal cancer: a multicentre randomised, controlled, phase III trial (the TAU-TEM study). Ann Oncol 2023; 34 (01) 78-90
- 54 Lynn PB, Van der Valk MJM, Claassen YHM. et al. Chemoradiation and local excision versus total mesorectal excision for T2N0 rectal cancer: comparison of short- and long-term outcomes from 2 prospective studies. Ann Surg 2023; 277 (01) e96-e102
- 55 Calmels M, Labiad C, Lelong B. et al. Local excision after neoadjuvant chemoradiotherapy for mid and low rectal cancer: a multicentric French study from the GRECCAR group. Colorectal Dis 2023; 25 (10) 1973-1980
